AGIO Jan 2025 45.000 call
| Previous Close | 1.7500 |
| Open | 3.9500 |
| Bid | 2.9000 |
| Ask | 3.8000 |
| Strike | 45.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 3.9500 - 3.9500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 25 |
GlobeNewswireAgios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 1:20 p.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A r
ZacksAgios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain cancer drug that was sold to Servier in 2021.
Investor's Business DailyAgios Breaks Out On 'Buffed Up' Financials After Inking Massive Brain Cancer Deal
Agios agreed Tuesday to sell its 15% royalty in a brain cancer drug for $905 million upfront. Agios stock broke out at the open.
